We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

135 hedge funds and large institutions have $265M invested in Rigel Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 33 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 8

58% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 33

13% more capital invested

Capital invested by funds: $234M → $265M (+$30.7M)

7% more funds holding

Funds holding: 126 → 135 (+9)

0.27% less ownership

Funds ownership: 8.87% → 8.6% (-0.27%)

10% less call options, than puts

Call options by funds: $44K | Put options by funds: $49K

Holders
135
Holders Change
+9
Holders Change %
+7.14%
% of All Funds
2.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
52
Reduced
33
Closed
8
Calls
$44K
Puts
$49K
Net Calls
-$5K
Net Calls Change
-$2K

Top Buyers

1
BlackRock
BlackRock
New York
+$4.2M
2
Renaissance Technologies
Renaissance Technologies
New York
+$2.89M
3
TA
Tamarack Advisers
California
+$2.34M
4
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$1.99M
5
JGC
J. Goldman & Co
New York
+$1.32M

Top Sellers

1
Millennium Management
Millennium Management
New York
-$13.7M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$7.07M
3
Goldman Sachs
Goldman Sachs
New York
-$3.42M
4
Morgan Stanley
Morgan Stanley
New York
-$2.07M
5
SI
Sofinnova Investments
California
-$1.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$39.3M -$1.05M -58,446 -3%
BlackRock
2
BlackRock
New York
$31.5M +$4.2M +233,730 +16%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$28.6M -$158K -8,788 -0.6%
Vanguard Group
4
Vanguard Group
Pennsylvania
$16.5M +$342K +19,021 +2%
TA
5
Tamarack Advisers
California
$12.5M +$2.34M +130,000 +23%
RSCM
6
Rock Springs Capital Management
Maryland
$10.8M +$715K +39,764 +7%
Renaissance Technologies
7
Renaissance Technologies
New York
$10.6M +$2.89M +160,856 +38%
Invesco
8
Invesco
Georgia
$9.17M +$108 +6 +0%
Citadel Advisors
9
Citadel Advisors
Florida
$8.39M +$1.22M +67,587 +17%
State Street
10
State Street
Massachusetts
$6.52M +$25.3K +1,406 +0.4%
PAI
11
Palo Alto Investors
California
$6.48M – – –
Hudson Bay Capital Management
12
Hudson Bay Capital Management
Connecticut
$6.07M -$326K -18,115 -5%
NMC
13
NEA Management Company
Maryland
$5.93M – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$4.57M +$118K +6,580 +3%
Northern Trust
15
Northern Trust
Illinois
$3.87M -$16.8K -935 -0.4%
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$3.81M -$338K -18,765 -8%
CS
17
Candriam SCA
Luxembourg
$3.56M -$900K -50,000 -20%
RPAM
18
Rhenman & Partners Asset Management
Sweden
$3.18M – – –
IC
19
Ikarian Capital
Texas
$3.08M – – –
Macquarie Group
20
Macquarie Group
Australia
$2.94M +$8.62K +479 +0.3%
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$2.58M +$175K +9,752 +7%
Jacobs Levy Equity Management
22
Jacobs Levy Equity Management
New Jersey
$2.57M +$1.06M +58,720 +72%
Morgan Stanley
23
Morgan Stanley
New York
$2.49M -$2.07M -114,905 -46%
Wells Fargo
24
Wells Fargo
California
$2.13M +$939K +52,213 +82%
Arrowstreet Capital
25
Arrowstreet Capital
Massachusetts
$2.02M +$1.99M +110,525 New
1
2 3 4 5

RIGL Hedge Fund Activity: Q2 2020 in Review

135 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2020, worth a combined $265M — up 13% from $234M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new RIGL positions and 8 closed out — a net gain of 10 holders — while 52 added to existing stakes and 33 trimmed.

The largest buyer was BlackRock, adding an estimated $4.2M. The largest seller was Millennium Management, cutting an estimated $13.7M.

  • 135 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2020, up from 126 in Q1 2020.
  • Funds reported $265M of Rigel Pharmaceuticals stock for Q2 2020, up 13% quarter-over-quarter.
  • 18 funds opened new Rigel Pharmaceuticals positions in Q2 2020 and 8 closed out, a net change of +10 holders.
  • The largest Rigel Pharmaceuticals buyer in Q2 2020 was BlackRock, an estimated $4.2M added.
  • The largest Rigel Pharmaceuticals seller in Q2 2020 was Millennium Management, an estimated $13.7M sold.

Based on aggregated 13F filings for Q2 2020.